The principal target organs for beryllium-related health effects are the skin and lungs. When workers are exposed to beryllium or its compounds, a small percentage develop granulomatous lung disease, known as chronic beryllium disease. In the beryllium extraction industry, a large percentage of workers develop contact dermatitis and/or beryllium skin ulcers in relation to soluble salt exposure. Historically, workers in extraction also were described as having chemical nasopharyngitis, tracheobronchitis, and/or pneumonitis with subacute onset, which resolved with cessation of exposure to beryllium salts and always within 1 year of symptom onset. In contrast, the chronic disease may develop after workers have left the beryllium industry, sometimes with a latency of several decades from first exposure. With workplace screening, latencies as short as a few weeks from first employment have been recognized.